Skip to content

Our technology

Targeted Active Therapy, in a nutshell

Rather than weakening the entire immune system, we neutralize only the antibodies responsible for the disease, using an antigen designed as the exact mirror of the target.

Mechanism of Action

CuraVac has developed a complementary peptide antigen based on the hydropathic profile of the autoantigen, mirroring its pattern following a lock-and-key logic.
This synthetic complementary peptide antigen is then linked to CRM-197, a carrier protein, and formulated with an adjuvant to create the treatment, ready for injection.

Following administration, CuraVac's treatment induces the production of complementary antibodies that bind to the disease-causing autoantibodies, rendering them unable to affect the acetylcholine receptors. With the autoantibodies neutralized, the acetylcholine can once again bind to the receptors. This allows the receptors to open their ion channels, enabling sodium ions to enter the muscle cells and trigger the electrical signal needed for muscle contraction. The neuromuscular function is therefore restored.

The solution

A molecular mirror, in four steps

Following a discovery by Prof. J. Edwin Blalock, CuraVac manufactures a complementary peptide and uses it as a Targeted Active Therapy.

  1. Autoantigen
    01

    The autoantigen

    A natural component of the body that carries a molecular “lock” (its immunogenic region) — in this case, the autoantigen targeted in myasthenia gravis.

  2. Autoantigen Autoimmune disease auto-Ab
    02

    The autoimmune disease

    Autoantibodies (auto‑Ab, in blue) bind to the acetylcholine receptor and block its normal function, thereby preventing the usual signal from passing through.

  3. Autoantigen Peptide Autoimmune disease auto-Ab
    03

    The complementary peptide

    CuraVac designs a complementary peptide: the exact mirror of the autoantigen's lock.

  4. Autoantigen Peptide Autoimmune disease Immunisation auto-Ab anti-auto-Ab
    04

    The immunization

    Injected as a Targeted Active Therapy, it induces anti‑autoantibodies (anti‑auto‑Ab, in green) that neutralize the harmful autoantibodies and restore normal function.

How is this a breakthrough?

The medications available today rely on aggressive alterations of the immune system: they reduce its overall effectiveness causing serious side effects, without addressing the underlying cause.

Current treatments

  • Weaken the entire immune system.
  • Significant side effects, requiring lifelong use.
  • Symptomatic or suppressive —no actual cure.

CuraVac's approach

  • Targets only the misguided part of the immune system, leaving normal defenses intact.
  • Preserves healthy immune functions.
  • Aims for lasting improvement, even remission.

“Restore patients' health for the long term, rather than treating the disease for life.”

At CuraVac, we believe in treating the disease, not in maintenance therapy.

One platform

Same technology, other diseases

Myasthenia gravis is our first target. Targeted active immunotherapy using complementary peptides can be extended to other autoimmune diseases, which affect an estimated 5 to 8% of the world’s population.

  • Myasthenia gravis · current target
  • Multiple sclerosis
  • Type 1 diabetes
  • Graves' disease
  • Lupus (SLE)
  • Hashimoto's disease
  • Rheumatoid arthritis

A platform validated in Phase 1b, ready for Phase 2

An excellent safety and tolerability profile, along with early signs of efficacy, was demonstrated in the Phase 1b trial for myasthenia gravis. We are seeking investors to fund the Phase 2 efficacy trial.